Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Cristiana Maria Grapa, Teodora Mocan, Diana Gonciar, Claudiu Zdrehus, Ofelia Mosteanu, Teodora Pop & Lucian Mocan. (2019) Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles. International Journal of Nanomedicine 14, pages 9693-9706.
Read now
Read now
Maria Diab, Asfar Azmi, Ramzi Mohammad & Philip A. Philip. (2019) Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opinion on Pharmacotherapy 20:5, pages 535-546.
Read now
Read now
Volker Fendrich & Matthias Lauth. (2014) The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer. Expert Opinion on Therapeutic Targets 18:11, pages 1277-1283.
Read now
Read now
Joji Kurian Thomas, Min-Sik Kim, Lavanya Balakrishnan, Vishalakshi Nanjappa, Rajesh Raju, Arivusudar Marimuthu, Aneesha Radhakrishnan, Babylakshmi Muthusamy, Aafaque Ahmad Khan, Sruthi Sakamuri, Shantal Gupta Tankala, Mukul Singal, Bipin Nair, Ravi Sirdeshmukh, Aditi Chatterjee, T S Keshava Prasad, Anirban Maitra, Harsha Gowda, Ralph H Hruban & Akhilesh Pandey. (2014) Pancreatic Cancer Database. Cancer Biology & Therapy 15:8, pages 963-967.
Read now
Read now
Carmine Carbone & Davide Melisi. (2012) NF-κB as a target for pancreatic cancer therapy. Expert Opinion on Therapeutic Targets 16:sup2, pages S1-S10.
Read now
Read now
Articles from other publishers (37)
Yue Zhao, Hanming Yao, Kege Yang, Shiji Han, Shangxiang Chen, Yaqing Li, Shaojie Chen, Kaihong Huang, Guoda Lian & Jiajia Li. (2022)
Arsenic trioxide-loaded nanoparticles enhance the chemosensitivity of gemcitabine in pancreatic cancer
via
the reversal of pancreatic stellate cell desmoplasia by targeting the AP4/galectin-1 pathway
. Biomaterials Science 10:20, pages 5989-6002.
Crossref
Crossref
Yijie You, Yunlian Niu, Jian Zhang, Sheng Huang, Peiyuan Ding, Fengbing Sun & Xuhui Wang. (2022) U0126: Not only a MAPK kinase inhibitor. Frontiers in Pharmacology 13.
Crossref
Crossref
Yongsheng Liu, Shengze Yu, Tianqi Xu, Vitalina Bodenko, Anna Orlova, Maryam Oroujeni, Sara S. Rinne, Vladimir Tolmachev, Anzhelika Vorobyeva & Torbjörn Gräslund. (2022) Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics 14:7, pages 1475.
Crossref
Crossref
Liangcai Zhao, Yiming Zhou, Zhibin Bai, Feng Zhang & Xiaoming Yang. (2022) The underlying molecular mechanism of intratumoral radiofrequency hyperthermia-enhanced chemotherapy of pancreatic cancer. Journal of Interventional Medicine 5:2, pages 57-63.
Crossref
Crossref
Francesca Simionato, Camilla Zecchetto, Valeria Merz, Alessandro Cavaliere, Simona Casalino, Marina Gaule, Mirko D’Onofrio, Giuseppe Malleo, Luca Landoni, Alessandro Esposito, Giovanni Marchegiani, Luca Casetti, Massimiliano Tuveri, Salvatore Paiella, Filippo Scopelliti, Alessandro Giardino, Isabella Frigerio, Paolo Regi, Paola Capelli, Stefano Gobbo, Armando Gabbrielli, Laura Bernardoni, Vita Fedele, Irene Rossi, Cristiana Piazzola, Serena Giacomazzi, Martina Pasquato, Morena Gianfortone, Stefano Milleri, Michele Milella, Giovanni Butturini, Roberto Salvia, Claudio Bassi & Davide Melisi. (2020) A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Therapeutic Advances in Medical Oncology 12, pages 175883592094796.
Crossref
Crossref
Ana De Jesus-Acosta, Amol Narang, Lauren Mauro, Joseph Herman, Elizabeth M. Jaffee & Daniel A. Laheru. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1342
1360.e7
.
Xiaodiao Kang, Zeng Lin, Minhui Xu, Jun Pan & Zhi‐wei Wang. (2019) Deciphering role of FGFR signalling pathway in pancreatic cancer. Cell Proliferation 52:3.
Crossref
Crossref
Maria Diab, Muhammad Saad Hamid, Ramzi M. Mohammad, Philip A. Philip & Asfar S. Azmi. 2019. Textbook of Gastrointestinal Oncology. Textbook of Gastrointestinal Oncology
479
491
.
C Carbone, G Piro, N Gaianigo, F Ligorio, R Santoro, V Merz, F Simionato, C Zecchetto, G Falco, G Conti, P T Kamga, M Krampera, F Di Nicolantonio, L De Franceschi, A Scarpa, G Tortora & D Melisi. (2017) Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. International Journal of Obesity 42:3, pages 334-343.
Crossref
Crossref
Carmine Carbone, Geny Piro, Valeria Merz, Francesca Simionato, Raffaela Santoro, Camilla Zecchetto, Giampaolo Tortora & Davide Melisi. (2018) Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer. International Journal of Molecular Sciences 19:2, pages 431.
Crossref
Crossref
Anna Schmitt, Georg Feldmann, Thomas Zander & H. Christian Reinhardt. (2018) Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. Oncology Research and Treatment 41:10, pages 619-625.
Crossref
Crossref
Nicola Gaianigo, Davide Melisi & Carmine Carbone. (2017) EMT and Treatment Resistance in Pancreatic Cancer. Cancers 9:12, pages 122.
Crossref
Crossref
Manoj Kumar, Sunil Kumar Dhatwalia & D. K. Dhawan. (2016) Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis. Tumor Biology 37:11, pages 14341-14354.
Crossref
Crossref
Todd B. ShelperCarrie J. LovittVicky M. Avery. (2016)
Assessing Drug Efficacy in a Miniaturized Pancreatic Cancer
In Vitro
3D Cell Culture Model
. ASSAY and Drug Development Technologies 14:7, pages 367-380.
Crossref
Crossref
Tao Yin, Zhengle Zhang, Bin Cao, Qingke Duan, Pengfei Shi, Hengqiang Zhao, Soriba Naby Camara, Qiang Shen & Chunyou Wang. (2016) Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine. Oncotarget 7:24, pages 37192-37204.
Crossref
Crossref
Nicola Fusco & Silvano Bosari. (2016)
HER2
aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists
. World Journal of Gastroenterology 22:35, pages 7926.
Crossref
Crossref
Joseph M. Herman, Christopher H. Crane, Christine Iacobuzio-Donahue & Ross A. Abrams. 2016. Clinical Radiation Oncology. Clinical Radiation Oncology
934
959.e6
.
David Fogelman, Milind Javle & James Abbruzzese. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research
255
262
.
MENG GUO, HUANHUAN WEI, JINGYING HU, SHAOYANG SUN, JIANG LONG & XU WANG. (2015) U0126 inhibits pancreatic cancer progression via the KRAS signaling pathway in a zebrafish xenotransplantation model. Oncology Reports 34:2, pages 699-706.
Crossref
Crossref
BEIBEI ZHANG, XIAORONG GUO, JINGXI ZHANG, XIAO LIU, XIANBAO ZHAN & ZHAOSHEN LI. (2014) MicroRNA-224 is downregulated in mucinous cystic neoplasms of the pancreas and may regulate tumorigenesis by targeting Jagged1. Molecular Medicine Reports 10:6, pages 3303-3309.
Crossref
Crossref
BENQUAN WANG, QIAN ZOU, MENG SUN, JINGFENG CHEN, TIANYANG WANG, YONGHENG BAI, ZONGJING CHEN, BICHENG CHEN & MENGTAO ZHOU. (2014) Reversion of trichostatin A resistance via inhibition of the Wnt signaling pathway in human pancreatic cancer cells. Oncology Reports 32:5, pages 2015-2022.
Crossref
Crossref
Matias E. Valsecchi, Enrique Díaz-Cantón, Máximo de la Vega & Susan J. Littman. (2013) Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. Journal of Gastrointestinal Cancer 45:2, pages 190-201.
Crossref
Crossref
Robert RoskoskiJr.Jr.. (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research 79, pages 34-74.
Crossref
Crossref
Lauren A. Mauro, Joseph M. Herman, Elizabeth M. Jaffee & Daniel A. Laheru. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1397
1415.e7
.
Kolaparthi Venkatasubbarao, Lindsay Peterson, Shujie Zhao, Ping Hill, Lin Cao, Qing Zhou, Steffan T Nawrocki & James W Freeman. (2013) Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Molecular Cancer 12:1.
Crossref
Crossref
Jodee L. Johnson & Elvira Gonzalez de Mejia. (2013) Flavonoid apigenin modified gene expression associated with inflammation and cancer and induced apoptosis in human pancreatic cancer cells through inhibition of GSK-3β/NF-κB signaling cascade. Molecular Nutrition & Food Research 57:12, pages 2112-2127.
Crossref
Crossref
Elena Kurenova, Jianqun Liao, Di-Hua He, Darrell Hunt, Michael Yemma, Wiam Bshara, Mukund Seshadri & William G. Cance. (2013) The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth. Oncotarget 4:10, pages 1632-1646.
Crossref
Crossref
S Zhao, L Cao & J W Freeman. (2013) Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines. Oncogenesis 2:10, pages e76-e76.
Crossref
Crossref
Kenji Yokoi, Biana Godin, Carol J. Oborn, Jenolyn F. Alexander, Xuewu Liu, Isaiah J. Fidler & Mauro Ferrari. (2013) Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. Cancer Letters 334:2, pages 319-327.
Crossref
Crossref
Deepali Bang, Willie Wilson, Meagan Ryan, Jen Jen Yeh & Albert S. Baldwin. (2013) GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB. Cancer Discovery 3:6, pages 690-703.
Crossref
Crossref
Marissa J. Stanton, Samikshan Dutta, Heyu Zhang, Navatha S. Polavaram, Alexey A. Leontovich, Pia Hönscheid, Frank A. Sinicrope, Donald J. Tindall, Michael H. Muders & Kaustubh Datta. (2013) Autophagy Control by the VEGF-C/NRP-2 Axis in Cancer and Its Implication for Treatment Resistance. Cancer Research 73:1, pages 160-171.
Crossref
Crossref
A Arlt, H Schäfer & H Kalthoff. (2012) The ‘N-factors’ in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer. Oncogenesis 1:11, pages e35-e35.
Crossref
Crossref
Shuiqing Hu, Qingqiong Luo, Biyun Cun, Dan Hu, Shengfang Ge, Xianqun Fan & Fuxiang Chen. (2012) The Pharmacological NF-κB Inhibitor BAY11-7082 Induces Cell Apoptosis and Inhibits the Migration of Human Uveal Melanoma Cells. International Journal of Molecular Sciences 13:12, pages 15653-15667.
Crossref
Crossref
H.L. Kindler, D.A. Richards, L.E. Garbo, E.B. Garon, J.J. StephensonJr.Jr., C.M. Rocha-Lima, H. Safran, D. Chan, D.M. Kocs, F. Galimi, J. McGreivy, S.L. Bray, Y. Hei, E.G. Feigal, E. Loh & C.S. Fuchs. (2012) A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology 23:11, pages 2834-2842.
Crossref
Crossref
L. V. Klotz, M. E. Eichhorn, B. Schwarz, H. Seeliger, M. K. Angele, K.-W. Jauch & Christiane J. Bruns. (2012) Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbeck's Archives of Surgery 397:4, pages 569-578.
Crossref
Crossref
Melchiorre Cervello, James A. McCubrey, Antonella Cusimano, Nadia Lampiasi, Antonina Azzolina & Giuseppe Montalto. (2012) Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 3:3, pages 236-260.
Crossref
Crossref
J Harder, G Ihorst, V Heinemann, R Hofheinz, M Moehler, P Buechler, G Kloeppel, C Röcken, M Bitzer, S Boeck, E Endlicher, A Reinacher-Schick, C Schmoor & M Geissler. (2012) Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. British Journal of Cancer 106:6, pages 1033-1038.
Crossref
Crossref